Oral non steroid anti-inflammatories for children and adults with bronchiectasis

  • Review
  • Intervention

Authors

  • Nitin Kapur,

    1. Menzies School of Health Research, Charles Darwin Uni & Qld Respiratory Childrens Centre, RCH, Child Health Division,, Brisbane, Queensland, Australia
    Search for more papers by this author
  • Anne B Chang

    Corresponding author
    1. Royal Children's Hospital, Brisbane and Menzies School of Health Research, CDU, Darwin, Queensland Children's Respiratory Centre and Queensland Medical Research Institute, Brisbane, Queensland, Australia
    • Anne B Chang, Queensland Children's Respiratory Centre and Queensland Medical Research Institute, Royal Children's Hospital, Brisbane and Menzies School of Health Research, CDU, Darwin, Herston Road, Herston, Brisbane, Queensland, 4029, Australia. annechang@ausdoctors.net. Anne.chang@menzies.edu.au.

    Search for more papers by this author

Abstract

Background

Bronchiectasis is increasing recognised as a co-morbidity in many respiratory illness. Anti inflammatory drugs may reduce the inflammatory cascade and thus reduce symptoms and slow long term pulmonary decline.

Objectives

To assess the role of non steroid anti inflammatory drugs (NSAIDs) on symptom control and natural history of the disease in children and adults with bronchiectasis.

Search methods

The Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Airways Group Specialised Register, MEDLINE and EMBASE databases were searched by the Cochrane Airways Group up to December 2008.

Selection criteria

Only randomised controlled trials were considered. Patients with radiological or clinical evidence of bronchiectasis were included. Patients with Cystic Fibrosis were excluded.

Data collection and analysis

The titles, abstracts and citations were independently reviewed by two reviewers to assess potential relevance for full review. No eligible trials were identified and thus no data were available for analysis.

Main results

No randomised or controlled trials were found.

Authors' conclusions

There are no randomised controlled that examined the effect of oral NSAIDs in patients with bronchiectasis. In view of some benefit shown by inhaled NSAIDs in bronchiectasis, RCTs are clearly needed to study the beneficial effect of oral NSAIDs in patients with bronchiectasis.

摘要

背景

口服非類固醇抗發炎藥物治療兒童及成人的支氣管擴張症

支氣管擴張症通常會伴隨其他許多種呼吸道疾病而發生。抗發炎藥物可能可以降低發炎程度進而減少其症狀並減緩長期肺部功能的衰退。

目標

本研究評估非類固醇抗發炎藥物(non steroid anti inflammatory drugs,NSAIDs)對氣管擴張症的成人及兒童症狀控制及疾病自然史上所扮演的角色。

搜尋策略

Cochrane Airways Group由Cochrane Central Register of Controlled Trials(CENTRAL)、Cochrane Airways Group Specialised Register、MEDLINE和 EMBASE資料庫進行檢索,檢索至2006年12月。

選擇標準

僅納入隨機對照試驗。有氣管擴張症放射診斷或臨床證據的病患都被納入研究中,但排除囊狀纖維化(Cystic Fibrosis)病患。

資料收集與分析

兩位審閱者分別審閱所有的標題、摘要和引證資料並評估其是否與本文獻回顧可能有關。沒有發現適合納入本文獻回顧的試驗,因此沒有數據可進行分析。

主要結論

沒有發現相關的臨床隨機對照試驗。

作者結論

目前並沒有隨機對照試驗檢閱支氣管擴張症病患使用口服式NSAID療效。看到些吸入式NSAID對支氣管擴張症的好處,但仍需要明確的RCT試驗來探討口服式NSAID對支氣管擴張病患的療效。

翻譯人

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

感染和發炎在支氣管擴張症病患的症候和疾病進展上扮演重要的角色。抗發炎藥物可能可以降低發炎的嚴重度,進而可對支氣管擴張病患有所助益。以Cochrane Airways Group提供的標準檢索方法並沒有找到可評估支氣管擴張病患服用NSAID效果的隨機性對照試驗。因此,目前仍無法建議支氣管擴張患者常規性服用NSAID。

Plain language summary

Oral non steroid anti-inflammatories for children and adults with bronchiectasis

Infection and inflammation play an important role in the symptomatology and disease progression in patients with bronchiectasis. Anti inflammatory drugs may reduce the inflammatory cascade and thus may be beneficial in people with bronchiectasis. Using the standard search module of the Cochrane Airways Group, no randomised controlled trials that assessed the use of oral non steroidal anti inflammatory drugs (NSAIDs) in bronchiectasis were found. Thus the routine use of NSAIDs in bronchiectasis cannot be recommended.